Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
TSHA Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
263.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
127.90%
TSHA Stock Analysis
TSHA
PE Ratio:
TSHA
PEG Ratio:
Not Available
TSHA
Forward EPS Growth (12 month):
0.00%
TSHA
PS Ratio:
185.9
TSHA
PSG Ratio:
0.5
TSHA
Forward Revenue Growth (12 month):
400.00%
TSHA Articles
No data was found